Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

scPharmaceuticals Inc. - Common Stock (NQ:SCPH)

2.330 -0.300 (-11.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about scPharmaceuticals Inc. - Common Stock

< Previous 1 2 3 Next >
Analyst Expectations For scPharmaceuticals's Future
Via Benzinga
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From scPharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For March 19, 2025
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
scPharmaceuticals's Earnings Outlook
Via Benzinga
Recap: scPharmaceuticals Q4 Earnings
Via Benzinga
A Preview Of scPharmaceuticals's Earnings
Via Benzinga
Recap: scPharmaceuticals Q3 Earnings
Via Benzinga
Wondering what's happening in today's after-hours session?
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
From scPharmaceuticals Inc.
Via GlobeNewswire
SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024
SCPH stock results show that scPharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization
FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuticals secures $125M non-dilutive financing to repay debt and advance... 
Via Benzinga
Exposures Product Safety
Earnings Preview: scPharmaceuticals
Via Benzinga
Earnings Outlook For scPharmaceuticals
Via Benzinga
The Latest Analyst Ratings for scPharmaceuticals
Via Benzinga
7 Short-Squeeze Stocks That Could Beat Down the Bears
Panic can be a cruel emotion, especially when the consequences are uncapped red ink. 
Via InvestorPlace
SCPH Stock Earnings: scPharmaceuticals Beats EPS, Beats Revenue for Q1 2024
SCPH stock results show that scPharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Earnings Outlook For scPharmaceuticals
Via Benzinga
Earnings Preview For scPharmaceuticals
Via Benzinga
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
Dow Up 150 Points; Gold Jumps Over 2%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Thursday. The Dow traded up 0.47% to 32,180.26 while the NASDAQ rose 1.29% to 11,820.77. The S&P... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
Analyst Ratings for scPharmaceuticals
Via Benzinga
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023. 
Via Benzinga
Nasdaq Surges Over 2%; Accenture To Reduce 19,000 Jobs
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.42% to 32,484.03 while the NASDAQ rose 2.40% to 11,949.60. The S&P 500,... 
Via Benzinga
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.